Molecular Diagnostics Rapid Multiplex PCR Platform

Sample anywhere,
trust the result.

Prime Discoveries built a rapid multiplex PCR platform that runs directly on multiple sample types — saliva, nasal, nasopharyngeal, sputum — with no upfront processing. Samples go direct to strip in under two minutes, and bead-based multiplexing reads many targets at once on the qPCR instruments labs already own. Direct from sample. Bead multiplexing. No cold chain. Minimal pipetting, minimal contamination. Clinical-grade results in under 60 minutes — deployable anywhere from a reference laboratory in New York to a community health post in Bihar.

See the technology View panel library

477

Microbial targets

Under
2 min

Sample to instrument

Under
60 min

Sample to result

135

Countries addressable

What Prime built

Most molecular diagnostics demand a lab: upfront processing, cold chain, dedicated instruments, and trained hands. That overhead — not the PCR itself — decides who gets tested and who doesn't.

Prime collapses that overhead into a single room-temperature strip. The sample goes on directly — saliva, nasal, nasopharyngeal, sputum, and more — and is ready for PCR in under two minutes. No centrifuge, no master-mix prep, no liquid-handling robot.

Bead-based multiplexing reads many targets in one reaction, and the strip runs on the qPCR instruments labs already own — Bio-Rad CFX96, ABI 7500, QuantStudio 3/5/6/7, or any instrument with FAM, VIC, and Texas Red channels. Minimal pipetting keeps contamination and plastic waste low. An extraction-free protocol detects straight from the sample, with no culture step.

The result: clinical-grade PCR with simultaneous AMR resistance gene profiling, deployable by a community health worker.

Eliminated

Conventional 01

Lysis

No chemical lysis buffers, heat, or bead-beating — the strip works straight from the raw sample.

Eliminated

Conventional 02

Extraction

No spin columns, wash buffers, or centrifuge — removing $5–15 and 25–45 min per test.

Eliminated

Conventional 03

Purification

No DNA cleanup or cold storage — detection runs directly on the sample matrix.

Simplified

Conventional 04

Reagent prep & plating

Lyophilised reagents pre-loaded on the strip — no master-mix prep, no freeze–thaw, minimal pipetting, no skilled technician. ~3 hrs of setup becomes under 2 minutes.

Prime Step 01

Most sample types — direct to strip

Saliva, nasal, nasopharyngeal, sputum, and more. No processing — sample to instrument in under two minutes. Self-collected or clinician-collected.

Prime Step 02

PCR amplification

Lyophilised reagents pre-loaded. Room-temperature stable up to 2 years. No cold chain. Runs on existing qPCR instruments.

Prime Step 03

Multiplex detection — many targets, one sample

Bead-based multiplexing screens for many targets in a single reaction. Across the instrument's fluorescence channels, each pathogen and resistance marker is resolved from the same sample — so one strip returns a full panel, not a single yes/no answer.

Multiple sample types

Prime runs directly on multiple sample types — saliva, nasal, nasopharyngeal, sputum, and more. The same lyophilised reagent strip functions in the inhibitor environment of each, with no protocol changes, no additional reagents, no dilution, and no upfront processing. Sample to instrument in under two minutes.

Urine

First-catch or mid-stream. Primary matrix for UTI, TB, and STI panels. Self-collected, no clinician required.

Saliva

Oral cavity sample. Oral health, respiratory, and systemic infection panels. Non-invasive collection.

Sputum

Lower respiratory tract. TB, pneumonia, and respiratory viral panels. Standard sputum collection or induced.

Swab

Nasopharyngeal, wound, vaginal, or rectal. Compatible with standard flocked swab collection.

Stool

Gastrointestinal, parasitology, and food-borne illness panels. Standard stool collection container.

30 panels · 477 targets

Every panel designed for the specific clinical decision it informs — not just pathogen detection, but treatment-guiding resistance gene profiling.

PD-P01

AMR Panel

40 targets

PD-P22

Pneumonia Panel

33 targets

PD-P21

Parasite Panel

30 targets

PD-P24

Sepsis Panel

24 targets

PD-P23

Respiratory Panel

23 targets

PD-P11

Gastrointestinal Panel

22 targets

PD-P32

Vector-borne Panel

22 targets

PD-P02

Antibiotic Resistance Panel

20 targets

PD-P16

MDR Panel

20 targets

PD-P05

Biosurveillance Panel

20 targets

+21 more

View full library

All 477 targets →

Life-saving diagnostics should be available to all.

Eleven million people develop Tuberculosis each year. Three hundred and seventy four million acquire STIs. One point two seven million die from antimicrobial resistance annually. The vast majority are diagnosed late, diagnosed wrong, or not diagnosed at all — not because the molecular tools don't exist, but because those tools require infrastructure that only exists in some countries. Prime was built to close that gap.

Simplifying Molecular testing

Direct-to-strip sampling, room-temperature reagents, and existing-instrument compatibility — not centrifuges, cold chain, or dedicated boxes.

Clinical grade at LMIC price

Priced for the populations who need it most — because a test that is clinically accurate but economically inaccessible is not a solution.

iii

AMR as a first-class problem

Pathogen identification plus resistance gene profiling in the same 60-minute reaction. Clinicians can now know which antibiotic actually works.

Partner with Prime Discoveries

We work with reference laboratories, testing companies, government health programs, pharmaceutical companies, and global health funders.

Get in touch About Prime

Platform Technology

Sample to result
in minutes.

Prime is a rapid multiplex PCR platform. Samples go direct to strip in under two minutes, amplify on the qPCR instruments labs already own, and return clinical-grade results in under 60 minutes — with no cold chain, minimal handling, and an extraction-free protocol that detects straight from the sample.

The Prime platform

Most molecular tests still demand a lab: upfront processing, cold chain, dedicated instruments, and trained staff. Prime collapses that into one room-temperature strip that runs directly on the sample, in minutes, on the qPCR instruments labs already own.

Conventional PCR workflow & Prime architecture

Step 01

Sample collection

Blood draw, invasive swab, or sputum — requiring trained clinical staff

Step 02

DNA extraction

$5–15 in reagents, 20–45 minutes, $40K+ liquid handling robot

Step 03

Sample purification

Column-based or bead-based cleanup, cold storage required

Prime enters here

Step 04

Reagent prep & plating

Lyophilised reagents pre-loaded on strip — no master-mix prep, no freeze–thaw, ~3 hrs → under 2 min.

Step 05

PCR amplification

Runs on existing qPCR instruments — Bio-Rad, ABI, QuantStudio — amplifying all panel targets at once.

Conventional steps eliminated by Prime

Prime extractionless workflow

Reagent prep simplified by Prime

<2 min

Sample to instrument — minimal pipetting

<60 min

Sample to clinical-grade result

2 yr

Room-temperature stability — no cold chain

Sample type

Runs directly on multiple sample types

Saliva, nasal, nasopharyngeal, sputum, and more go direct to strip in under two minutes — no pre-processing, no lysis, no extraction. No clinical staff required for collection. Self-administration in any setting — clinic, home, community health post, or agricultural cooperative.

Chemistry

Lyophilised reagent strip

Proprietary lyophilisation stabilises PCR reagents — enzymes, primers, probes, buffers — at room temperature for up to 2 years. No cold chain, no freeze/thaw, no master-mix prep, and no liquid-handling robots. Ships to Lagos or Lucknow ambient.

Detection

Bead-based multiplexing

Bead-based multiplexing reads many targets in one reaction across FAM, VIC, and Texas Red channels. AI-designed assays are screened against closely related species to rule out cross-reactivity. The same sample that screens for TB also reveals rifampicin and isoniazid resistance — telling clinicians which drug actually works.

AMR intelligence

Real-time resistance profiling

Where standard culture takes 48–72 hours to return antibiotic sensitivity, Prime returns AMR resistance gene profiles alongside pathogen identification in 90 minutes. Clinicians know which antibiotic works before the patient leaves the clinic. In UTI, wound care, and respiratory settings, this single capability changes treatment decisions and reduces inappropriate antibiotic prescribing at population scale.

Instruments

Runs on existing qPCR instruments

Compatible with Bio-Rad CFX96, ABI 7500, and QuantStudio 3, 5, 6, and 7 — or any qPCR instrument with FAM, VIC, and Texas Red channels. No proprietary box, no service contracts. Custom kits can be built in 3–4 weeks.

The problem with lab-bound testing

Every molecular diagnostic in existence — GeneXpert, BioFire, Abbott ID NOW — is built for the lab: dedicated instruments, cold-chain reagents, multi-step processing, and trained staff. That overhead, not the biology, is what keeps testing out of reach.

DNA extraction requires a centrifuge, a heat block, column-based reagents, and trained technical staff. It adds $5–15 in reagent costs and 20–45 minutes to every test. It requires a cold chain for reagent storage. It requires $40,000 in liquid handling equipment for high-throughput deployment. These requirements confine molecular diagnostics to facilities with infrastructure — hospitals, centralised reference laboratories, university research centres.

The consequence: five billion people live in settings where that infrastructure does not exist. In sub-Saharan Africa, South Asia, and Southeast Asia — where tuberculosis, drug-resistant infections, and neglected tropical diseases are most prevalent — molecular confirmation of diagnosis is unavailable to most patients. Clinicians diagnose empirically. Antibiotics are prescribed without knowing which pathogen is present. Drug-resistant infections go undetected until treatment failure forces a second visit that may not happen.

This is not a funding problem or a political problem. It is an infrastructure problem with a technical solution. Prime built the solution.

11M

New TB cases per year globally87% occur in LMIC settings where molecular TB diagnosis is unavailable to most patients

374M

New STI cases per yearThe vast majority are undiagnosed because no affordable POC molecular test exists at scale

1.27M

AMR deaths annuallyGrowing. Driven by empirical antibiotic prescribing in the absence of resistance profiling at the point of care

$15

Cost of DNA extraction per testRemoved — Prime detects straight from the sample, no extraction step

How the Prime chemistry works

Prime's platform rests on a proprietary chemistry: PCR reagents that are thermostabilised, lyophilised, and pre-loaded onto a diagnostic strip — ready to amplify directly from saliva, nasal, nasopharyngeal, or sputum samples with no upfront processing. Bead-based multiplexing reads many targets at once across FAM, VIC, and Texas Red channels, and AI-designed assays are screened against closely related species to rule out cross-reactivity. Sample to instrument takes under two minutes; sample to result, under 60.

Pillar 01

Sample matrix compatibility

Every biological sample matrix contains PCR inhibitors — organic acids, proteins, salts, and nucleases — that denature conventional PCR enzymes and produce false negatives. Prime's sample collection formulation is specifically optimised to function directly within biological sample matrices — urine, saliva, sputum, swabs, and stool — eliminating the need for any cleanup, dilution, extraction, inactivation, or lysis step prior to amplification.

Direct
from sample

No extraction or dilution

Pillar 02

Lyophilisation formulation

Prime's reagents — enzymes, primers, probes, buffers, and internal controls — are lyophilised into a single pellet pre-loaded onto the diagnostic strip. Lyophilisation removes water under vacuum at low temperature, preserving enzyme activity in a dry, stable matrix. The result is a reagent system that survives ambient temperatures for 2 years without refrigeration — eliminating cold chain entirely. The same strip that ships to Lagos at ambient temperature runs in a New York reference laboratory with identical performance.

2 years

Room temperature stable

How lyophilisation makes ambient PCR possible

Lyophilisation — freeze-drying — is not new to diagnostics. Lateral flow antigens have been lyophilised for decades. What Prime achieved is extending this stability to the full PCR reaction chemistry: polymerase enzymes, dNTPs, MgCl₂, primers, fluorescent probes, and internal controls, all in a single co-lyophilised pellet that reconstitutes correctly in a multi-sample matrix.

The co-formulation challenge is significant. Each component has different optimal stabilisation conditions. Getting all of them to survive lyophilisation and reconstitute in the correct stoichiometric ratios — reliably, across manufacturing batches, across 2 years of storage — required systematic formulation optimisation that constitutes the core of Prime's technical moat.

Formulation

All PCR components combined with cryoprotectants, excipients, and stabilisers in precise ratios optimised for the target matrix

Freeze-drying

Primary drying removes ice under vacuum. Secondary drying removes bound water. Final moisture content <2% for maximum stability

Strip integration

Lyophilised pellet deposited onto the PCR reaction zone. Strip sealed under nitrogen atmosphere.

Reconstitution in use

Sample added directly — urine, saliva, sputum, swab, or stool. Pellet reconstitutes in the sample matrix. PCR reaction initiates without any additional reagents or steps in less than 2 minutes.

Thermal cycling and detection

Standard thermocycler or Prime-integrated reader runs the PCR programme. Fluorescence curve analysis distinguishes pathogens and resistance genes simultaneously

From sample to result

The conventional molecular diagnostic workflow contains seven steps before a result is returned. Prime's workflow contains two. The steps that Prime eliminated are not shortcuts — they are steps that Prime made unnecessary by design.

Conventional only

Eliminated by Prime

Invasive sample collection

Many conventional molecular tests require invasive or specialised collection — sputum induction, for example, needs a trained clinician and a negative-pressure booth.

Requires trained clinician Special collection facility

Conventional only

Eliminated by Prime

Sample lysis

Breaking open cells and pathogens to release nucleic acid requires chemical lysis buffers and either heat or mechanical disruption. Tough-walled organisms can demand additional bead-beating or harsher chemical protocols — none of it compatible with simple workflows.

Specialised reagents 15–20 min protocol

Conventional only

Eliminated by Prime

DNA extraction and purification

Column-based silica membrane extraction binds DNA while washing away inhibitors. This step requires a centrifuge, column reagents, multiple wash buffers, and trained hands. It costs $5–15 per test in consumables and 25–40 minutes per run. The equipment required costs $5,000–$40,000. This single step is responsible for the vast majority of the infrastructure barrier to molecular diagnostics in LMIC settings.

$5–15 per test 25–40 minutes $5–40K instrument

Prime enters here — no extraction required

Simplified by Prime

Reagent preparation & plating

Conventional qPCR needs a master mix built by hand — thawing enzyme, buffer, dNTPs, primers, and probes on ice, then pipetting into every well. For a multiplex panel across a 96-well plate that can mean loading close to a hundred reactions by hand or by liquid-handling robot, with freeze–thaw cycles that degrade reagents and pipetting errors that ruin runs. Prime pre-loads lyophilised reagents onto the strip — no master-mix preparation, no freeze–thaw, minimal pipetting, and no skilled technician required. Setup that conventionally takes around three hours is done in under two minutes.

~3 hrs → under 2 min No master-mix prep No freeze–thaw or robot

Prime step

Self-collected sample — no processing

The patient collects a sample — saliva, nasal, nasopharyngeal, sputum, or another matrix depending on the panel — into Prime collection media. No lysis, extraction, or purification. The sample ships at ambient temperature to the testing laboratory, where it is applied directly to the Prime strip in under two minutes. That is the entire sample preparation step.

Self-collected No processing Ships ambient to lab

Prime step

PCR amplification and fluorescence curve analysis

The lyophilised reagent pellet reconstitutes directly in the sample matrix. The strip is placed in a standard qPCR instrument — Bio-Rad CFX96, ABI 7500, or QuantStudio 3/5/6/7. Real-time qPCR cycling runs — denaturation, annealing, extension — amplifying all panel targets simultaneously across the FAM, VIC, and Texas Red channels. Each pathogen and each resistance-gene variant produces a characteristic fluorescence signal.

Multiplex PCR Simultaneous multi-analyte 60–90 min total

Prime step

Multiplex detection — many targets, one sample

Bead-based multiplexing lets a single reaction screen for many targets at once. Across the instrument's fluorescence channels, each pathogen and resistance marker is resolved from the same sample — so one strip returns a full panel result rather than a single yes/no answer.

Bead-based multiplexing Many targets per sample One reaction

AMR resistance intelligence

Standard molecular diagnostics answer one question: is the pathogen present? Prime answers a second question that standard diagnostics cannot: which resistance genes does the pathogen carry, and which antibiotic will actually work?

TB — Drug resistance profiling

rpoB, katG, embB — in a single test

Rifampicin resistance is detected by mutations in the rpoB gene, isoniazid by katG, and ethambutol by embB. Prime's TB panel identifies M. Tuberculosis and can simultaneously profile all three resistance loci — distinguishing drug-sensitive TB from MDR-TB from XDR-TB in the same 60-minute reaction. Information that previously required culture-based drug-sensitivity testing taking 4–8 weeks could arrive before the patient leaves the clinic.

UTI — ESBL and carbapenem resistance

E. coli ESBL, KPC, NDM — 60 minutes

ESBL-producing E. coli now accounts for 15% of US UTI isolates and over 60% of UTI isolates in some South Asian populations. Standard urine culture takes 48–72 hours to return susceptibility results. Prime's UTI panel identifies the causative organism and profiles for ESBL, KPC, NDM, and OXA carbapenemase genes simultaneously — enabling targeted therapy instead of empirical broad-spectrum antibiotics that drive resistance in the very patients who need treatment most.

Wound care — MRSA characterisation

mecA, vanA, PVL toxin — wound management

MRSA wound infections require specific antibiotic regimens. But not all mecA-positive S. aureus is equally virulent — the presence of the PVL toxin gene marks strains with significantly higher tissue invasiveness. Prime's wound care panel identifies MRSA and simultaneously characterises virulence and resistance profile — informing both the antibiotic choice and the surgical management decision in a single test that takes 90 minutes instead of 3 days for culture results.

Platform	Sample type	Extraction required	Time to result	AMR resistance profiling	Instrument cost	LMIC deployable
Prime Discoveries	Multiple sample types	None	60–90 min	Yes — full gene panel	$0	Yes
Cepheid GeneXpert	Sputum / swab	Integrated cartridge	90–120 min	rifampicin only (TB)	$17,000+	Partial
BioFire FilmArray	Swab / blood	Integrated cartridge	60 min	No	$39,000+	No
Abbott ID NOW	Swab	Integrated	15 min	No	$2,800	Partial
Biomeme Franklin	Swab / nasal	Integrated cartridge	60–90 min	No	$4,995	Yes
Standard urine culture	Urine (catheter often)	N/A (culture-based)	48–72 hours	Phenotypic only	Lab infrastructure	Yes

The 477-target panel library

Prime's rapid, lyophilised PCR panels are the platform; the 477-target library is its application to clinical need. Primers are designed with AI assay selection and screened against closely related species to avoid cross-reactivity, probes synthesised, and analytical sensitivity, specificity, and limit of detection characterised in the appropriate sample matrix. Custom kits can be built in 3–4 weeks.

Infectious disease

TB + Drug Resistance

M. tuberculosis complex
rpoB (rifampicin resistance)
katG (isoniazid resistance)
embB (ethambutol resistance)
NTM differentiation panel

Infectious disease

STI Panel

Neisseria gonorrhoeae
Chlamydia trachomatis
Trichomonas vaginalis
Treponema pallidum
Mycoplasma genitalium

Infectious disease

UTI + AMR Panel

E. coli + ESBL genes (blaCTX-M)
Klebsiella pneumoniae
Enterococcus faecalis/faecium
Pseudomonas aeruginosa
KPC, NDM, OXA carbapenemases

Oncology prevention

HPV + H. pylori

HPV 16, 18, 31, 33, 45, 52, 58
H. pylori detection
CagA virulence gene (gastric cancer risk)
Fusobacterium nucleatum (CRC risk)

Infectious disease

Wound Care

S. aureus (PVL toxin)
Pseudomonas aeruginosa
Acinetobacter baumannii
vanA, vanB (vancomycin resistance)

Microbiome

Gut Health Panel

H. pylori + CagA
Faecalibacterium prausnitzii
Akkermansia muciniphila
Clostridioides difficile
E. coli O157:H7

Infectious disease

Respiratory Panel

Influenza A / B
RSV A / B
SARS-CoV-2
Mycoplasma pneumoniae
Legionella pneumophila

Infectious disease

Malaria

P. falciparum (with resistance genes)
P. vivax, P. malariae, P. ovale

477

Total targets

Clinical panel categories

135

LMIC countries addressable

Manufacturing and deployment

The room-temperature strip format ships ambient, requiring no cold chain. Because it runs on the qPCR instruments labs already own, a single arrangement with a regional master distributor can activate an entire country's diagnostic capacity — no new instruments to install, no service contracts, no cold-chain logistics to manage.

Validate the technology

We work with reference laboratories, hospital systems, and global health institutions to validate and deploy Prime's rapid PCR platform. If you are evaluating molecular diagnostic solutions for populations underserved by current platforms, we welcome a technical conversation.

Request technical data View full panel library

Panel Library 30 panels · 477 targets

Pathogen detection.
Resistance profiling.
One panel.

Every panel runs on Prime's extractionless PCR platform — multiple sample types, no extraction step, no cold chain. Targets designed for the specific clinical decision each panel informs: not just identification, but treatment-guiding AMR resistance gene profiling.

477

Total targets

Clinical panel categories

Sample matrix types

30 panels

PD-P01

AMR / Resistance

AMR Panel

40 targets

Broad antimicrobial-resistance gene detection — carbapenemases (KPC, NDM, VIM, OXA-48), ESBL, mecA, vanA/B, and colistin (mcr-1–5).

Resistance screening before treatment, AMR surveillance, infection control

PD-P02

AMR / Resistance

Antibiotic Resistance Panel

20 targets

Focused resistance screen — mecA (MRSA), vanA/B (VRE), KPC, NDM, OXA-48, ESBL, and colistin.

Pre-op MRSA/VRE screening, carriage surveillance, stewardship

PD-P03

Biosecurity

Bio-defense Panel

15 targets

CDC Category A–C agents — anthrax, plague, tularemia, smallpox, Ebola, Marburg, and select toxins.

Bioterror response, military field screening, threat assessment

PD-P04

Biosafety / QC

Biosafety Panel

35 targets

Cell-culture contaminant screen — Mycoplasma spp. plus adventitious viral and bacterial agents.

Pharmaceutical QC, cell-line authentication, biomanufacturing

PD-P05

Biosecurity

Biosurveillance Panel

20 targets

Population-level monitoring across priority bacterial, viral, and resistance markers.

Outbreak surveillance, public-health monitoring, sentinel networks

PD-P06

Respiratory

Covid-19 Panel

5 targets

SARS-CoV-2 detection with variant-relevant targets.

Acute COVID-19 diagnosis, screening, surveillance

PD-P07

Respiratory

FluVid Panel

6 targets

Combined Influenza A/B, RSV, and SARS-CoV-2 detection in one reaction.

Winter respiratory triage, influenza-like-illness differentiation

PD-P08

Food Safety

Food & Water Panel

18 targets

Foodborne and waterborne pathogens — Salmonella, Shigella, Listeria, E. coli O157, Vibrio, Cryptosporidium.

Outbreak investigation, food and water safety, environmental testing

PD-P09

GI / Enteric

Gastrointestinal Panel

22 targets

Bacterial, viral, and parasitic causes of diarrhoeal illness in one test.

Acute gastroenteritis, traveller's diarrhoea, outbreak workup

PD-P10

Tropical Medicine

Global Fever Panel

25 targets

Broad febrile-illness screen spanning malaria, arboviruses, and bacterial causes.

Undifferentiated fever, returning travellers, endemic settings

PD-P11

Hospital Infection

Healthcare Associated Infection (HAI) Panel

15 targets

Common nosocomial organisms plus their key resistance genes.

Hospital infection control, outbreak tracing, surveillance

PD-P12

Liver / Hepatitis

Hepatitis Panel

7 targets

Viral hepatitis A through E in a single reaction.

Acute and chronic hepatitis workup, screening, staging

PD-P13

Neurology / CNS

Meningitis / Encephalitis Panel

14 targets

Bacterial, viral, and fungal causes of meningitis and encephalitis.

Acute CNS infection, CSF workup, neonatal sepsis

PD-P14

AMR / Resistance

Multi-drug Resistance (MDR) Panel

20 targets

MDR/XDR resistance markers across Gram-negatives and TB loci.

MDR screening, escalation decisions, stewardship

PD-P15

Ophthalmology

Ophthalmic Panel

8 targets

Causes of infectious keratitis, conjunctivitis, and endophthalmitis.

Sight-threatening eye infection, contact-lens keratitis

PD-P16

Oral Health

Oral Health Panel

8 targets

Periodontal and oral pathogens linked to disease and systemic risk.

Periodontitis workup, oral-systemic risk, dental research

PD-P17

Transplant

Organ Transplant Panel

12 targets

Opportunistic infections in immunosuppressed recipients — CMV, EBV, BK, and more.

Post-transplant monitoring, immunosuppression, donor screening

PD-P18

Parasitology

Parasite Panel

30 targets

Broad protozoa and helminth detection across blood, gut, and tissue parasites.

Parasitic infection workup, endemic settings, eosinophilia

PD-P19

Respiratory

Pneumonia Panel

33 targets

Bacterial, viral, and fungal causes of community- and hospital-acquired pneumonia.

CAP / HAP / VAP workup, severe respiratory infection

PD-P20

Respiratory

Respiratory Panel

23 targets

Common respiratory viruses and atypical bacteria in one reaction.

Upper/lower respiratory infection, ILI triage, paediatrics

PD-P21

Critical Care

Sepsis Panel

24 targets

Rapid bloodstream pathogen ID with key resistance genes for sepsis.

Suspected sepsis, ICU, time-critical pathogen ID

PD-P22

Wound Care

Skin & Soft Tissue Panel

12 targets

Wound and soft-tissue organisms plus resistance markers (S. aureus, PVL, vanA/B).

Wound infection, abscess, diabetic foot, surgical site

PD-P23

Sexual Health

STI Panel

7 targets

Core sexually transmitted infections — chlamydia, gonorrhoea, trichomonas, mycoplasma.

STI screening, symptomatic workup, partner testing

PD-P24

Infectious Disease

TB Panel

12 targets

M. Tuberculosis detection with first-line resistance loci (rpoB, katG, inhA, embB).

TB diagnosis, MDR/XDR profiling, treatment selection

PD-P25

Vector-borne

Tick-borne Panel

8 targets

Tick-transmitted pathogens — Borrelia (Lyme), Anaplasma, Ehrlichia, Rickettsia, Babesia.

Tick-bite illness, Lyme workup, febrile exposure

PD-P26

Women's Health

ToRCH Panel

8 targets

Congenital-infection screen — Toxoplasma, Rubella, CMV, HSV, and others.

Antenatal screening, congenital infection, neonatal workup

PD-P27

Tropical Medicine

Tropical Fever Panel

18 targets

Acute tropical febrile illness — malaria, dengue, chikungunya, typhoid, leptospira.

Tropical fever, returning travellers, endemic outbreaks

PD-P28

Infectious Disease

Urinary Tract Infection Panel

12 targets

Uropathogens with resistance genes (ESBL, KPC, NDM) for targeted therapy.

Complicated/recurrent UTI, pyelonephritis, stewardship

PD-P29

Women's Health

Vaginal Health Panel

8 targets

Bacterial vaginosis, candidiasis, and common vaginal pathogens.

Vaginitis workup, recurrent symptoms, women's health

PD-P30

Vector-borne

Vector-borne Panel

22 targets

Mosquito- and tick-borne pathogens across arboviruses and parasites.

Vector-borne fever, outbreak settings, endemic surveillance

No panels match your search.

Request panel specifications

Technical data sheets, analytical validation reports, and clinical performance data are available for qualified laboratory and institutional partners. Contact us or reach us through our India distribution partner SPL.

Request data Platform overview

About Prime Discoveries

Molecular diagnostics
without limits.

We built a rapid multiplex PCR platform that runs directly on multiple sample types — sample to instrument in under two minutes, results in under 60. It needs no cold chain and almost no hands-on handling, and it runs on the qPCR instruments labs already own. One room-temperature strip. Deployable anywhere on earth.

Where this came from

Prime Discoveries was founded in 2018 with a single conviction: the fundamental bottleneck in global diagnostics was not the PCR chemistry itself, but everything that surrounded it. Every molecular diagnostic platform in existence — from GeneXpert to BioFire — required not just extraction but reagent prep and loading, freeze-thaw cycling, and wastage. Eliminating all of it would change everything.

That conviction — that the extraction step was the problem, not the PCR chemistry itself — guides every product decision Prime makes today. The same insight that began on a laboratory bench in 2018 is now a GMP-manufactured, clinically validated platform deployed across two continents.

The founding team brings together computational biology, venture capital, and life sciences, having built genetic testing companies including Recombine and Phosphorus and conducted R&D at Genentech, Cooper Genomics, and other leading research groups. Their combined expertise spans genomics, microbiology, artificial intelligence, bioinformatics, and cloud-scale engineering — the full set of capabilities required to design and deploy novel diagnostic tests.

Mission and principles

Life-saving diagnostics
should be available to all.

Eleven million people develop Tuberculosis each year. Three hundred and seventy four million acquire sexually transmitted infections. Two hundred and forty nine million contract malaria. The vast majority are diagnosed late, diagnosed wrong, or not diagnosed at all — not because the molecular tools do not exist, but because those tools require infrastructure that only exists in some countries.

Prime was built to close that gap permanently.

Access first

Every product decision is evaluated against one criterion: does this make molecular diagnostics more accessible to the 5 billion people who currently lack it? If it needs lab infrastructure — cold chain, dedicated instruments, or upfront processing — it fails the test.

Clinical grade at LMIC price

A test that is clinically accurate but economically inaccessible is not a solution. Prime prices its panels for the populations who need them most.

iii

AMR as a first-class problem

Antimicrobial resistance kills 1.27 million people annually and is growing. Prime's platform identifies not just which pathogen is present, but which resistance genes it carries — enabling targeted therapy instead of empirical treatment that drives resistance further.

Our Collaborators

We have worked with and are collaborating with a number of academic institutions, corporations, medical schools, and accelerators on research and new product development.

Our Scientific Advisors

We are advised by leading experts in applied genomics, computational biology, sequencing, medicine, microbiology, public health, and immunology.

Dr. George Church

Professor of Genetics, Harvard Medical School

Dr. Kristin Gunsalus

Professor of Biology, NYU CGSB/NYUAD

Dr. Daniel Grosu

Former Chief Medical Officer, Illumina

Work with Prime Discoveries

We partner with reference laboratories, government diagnostic programmes, pharmaceutical companies, and global health funders. If you are building diagnostic infrastructure for populations that conventional molecular testing has failed to reach, we want to hear from you.

Get in touch Read the science

Contact Prime Discoveries

Work with us.
Deploy everywhere.

Prime Discoveries partners with reference laboratories, testing companies, hospital systems, government health programs, pharmaceutical companies, and global health funders.

Primary distributor — India & South Asia

GMP Manufacturing & Distribution Partner

SPL India

SPL India is Prime Discoveries' exclusive distribution partner for India and South Asia.

SPL's distribution network covers India and the Middle East.

SPL India — Contact

Organisation

SPL Labs India

Business address

SPL Labs India

2/253 A, Thrissur, Kerala, India — PIN 680662

Web

www.splil.in

info@splil.in

Product lines

All Prime panel categories · All sample matrices

MOQ and tiered pricing available on request

Secondary distributor — Africa

Distribution Partner — Africa

OneVita Partners

OneVita Partners for Africa is Prime Discoveries' distribution partner for the African region.

OneVita Partners — Contact

Organisation

OneVita Partners for Africa

Business address

OneVita Partners for Africa

213 Winchester Ct, Suite #1, Voorhees, NJ 08043, USA

Web

www.onevitapartners.com

contact@onevitapartners.com

Product lines

All Prime panel categories · All sample matrices

MOQ and tiered pricing available on request

What are you looking for?

Enquiry type 02

Reference laboratory partnership

LDT launch support, panel validation protocols, and commercial agreements for US and international reference laboratories.

→ Contact Prime Discoveries

Enquiry type 03

Clinical validation & research

Academic and research institution partnerships, clinical validation study design, ICMR or equivalent regulatory validation support.

→ Contact Prime Discoveries

Enquiry type 04

Government & public health programs

National TB programme integration, Ministry of Health procurement, WHO PQ reliance discussions, LMIC government diagnostic programme deployment.

→ Contact Prime Discoveries

Enquiry type 05

Pharmaceutical & CDx partnerships

Companion diagnostic co-development, AMR Sentinel data licensing, pharmacogenomics panel integration, and clinical trial site access through Prime's lab network.

→ Contact Prime Discoveries

Enquiry type 06

Global health funding

Philanthropic programme partnerships, NIAID, BARDA, or USAID procurement discussions, and NGO deployment support.

→ Contact Prime Discoveries

Contact Prime Discoveries directly

Prime Discoveries is headquartered in New York City. Our scientific operations are based in Dallas, Texas. Our India operations are managed through SPL in partnership with our research collaborators.

CEO — Eugene Joseph

eugene@primediscoveries.com

Strategic partnerships, investor relations, government

Scientific enquiries — Dr. Arun Manoharan

arun@primediscoveries.com

Validation data, technical specifications, research

Headquarters

New York, NY · United States

Scientific operations: Dallas, Texas

Sample anywhere,trust the result.

What Prime built

Multiple sample types

30 panels · 477 targets

Life-saving diagnostics should be available to all.

Partner with Prime Discoveries

Sample to result in minutes.

The Prime platform

The problem with lab-bound testing

How the Prime chemistry works

How lyophilisation makes ambient PCR possible

From sample to result

AMR resistance intelligence

The 477-target panel library

Validate the technology

Pathogen detection.Resistance profiling.One panel.

Request panel specifications

Molecular diagnostics without limits.

Where this came from

Mission and principles

Life-saving diagnostics should be available to all.

Our Collaborators

Our Scientific Advisors

Work with Prime Discoveries

Work with us.Deploy everywhere.

Primary distributor — India & South Asia

Secondary distributor — Africa

What are you looking for?

Contact Prime Discoveries directly

Sample anywhere,
trust the result.

Sample to result
in minutes.

Pathogen detection.
Resistance profiling.
One panel.

Molecular diagnostics
without limits.

Life-saving diagnostics
should be available to all.

Work with us.
Deploy everywhere.